Newsletter | May 12, 2020

05.12.20 -- Inside ARM's A-Gene

 
From The Editor

Greetings Cell & Gene readers,

 

The Alliance for Regenerative Medicine (ARM) has brought together more than 50 experts from some of the preeminent gene therapy developers and manufacturers worldwide to create A-Gene, a reference guide for gene therapy development scheduled for release this summer. Drawing on the experience of contributors from across the development timeline, A-Gene will be a consensus-based guide for companies in the sector.

 

Orgenesis is a global biotech company that is unlocking the full potential of personalized therapies and closed processing systems through its Cell & Gene Therapy Biotech Platform. I had the opportunity to talk to Orgenesis’s CEO, Vered Caplan, about why the company sold its CDMO subsidiary, Masthercell, the importance of partnerships in driving down therapy costs, and more. Here’s what she had to say.

 

Stay safe!

 

Erin Harris, editor in chief
Follow me on Twitter

Industry Insights
Scalable Strategies For Parenteral Dosage Form Selection

Understand the strategies that can be employed at the different stages of development when choosing parenteral dosage forms.

Modular Facility Design Considerations For Biomanufacturing Facilities

For many companies, flexibility, scheduling, and facility-size reduction are the key drivers around the attention given to modular facility design for biomanufacturing facilities.

Strategic CDMO: Bringing End-To-End Solutions For Faster Drug Development

Patheon's Bill Weiser discusses how a new generation of CDMOs have positioned themselves to provide strategic solutions that not only complement product development but drive therapies to patients faster.

Codetection Of Viral Pathogen RNA And DNA Using One-Step Multiplex RT-qPCR

RT-qPCR is a well-established method for the detection, quantification, and typing of different microbial agents in the areas of clinical and veterinary diagnostics, as well as food safety. There are multiple benefits of this technology. In this application note, we demonstrate a sensitive codetection of viral RNA and DNA targets in a multiplex setting using a novel one-step multiplex RT-qPCR supermix.

How To Speed Up Cell And Gene Therapy Treatments For Patients, Reduce The Number Of Manual Operations, And Eliminate Operator Errors

This white paper addresses the unique production problems of cell and gene therapy and explains how a manufacturing execution system (MES) can address them. It provides guidance on how to select an MES and a case study of two CAR-T therapy companies scaling up with and without an MES.

Pairing Data Connectivity, Automation Ease Tech Transfer/Scale-Up

In biopharma, process data is used in many ways throughout process development and production phases. This article outlines how connectivity and comprehensive automation ease tech transfer and scale-up.

Custom-Designed Clinical Manufacturing Cleanrooms For Penn Medicine’s Cell And Gene Therapy Operations

A GMP manufacturing suite was developed that included a custom-designed and constructed clinical manufacturing cleanroom core for producing PENN Medicine's cell and gene therapy candidates.

Process Impurities: Don’t Let PEI Or HCP Derail Your Biotherapy

This presentation addresses product characterization strategies to de-risk the manufacturing of monoclonal antibodies (mAbs) and cell and gene therapies. It also covers detection and characterization of host cell proteins (HCPs) (a factor in mAb therapies and cell and gene therapies) and polyethylenimine (PEI) used in cell and gene therapies.

Solutions